Actinogen Medical (ASX:ACW) Short-Term Debt: A$0.08 Mil (As of Dec. 2025)


What is Actinogen Medical Short-Term Debt?

Actinogen Medical ASX:ACW +12.82% Short-Term Debt is A$0.08 Mil as of Dec. 2025. The stock has 4 warning signs investors should review.

Actinogen Medical's Short-Term Debt for the quarter that ended in Dec. 2025 was A$0.08 Mil.

Actinogen Medical's quarterly Short-Term Debt increased from Dec. 2024 (A$0.07 Mil) to Jun. 2025 (A$3.01 Mil) but then declined from Jun. 2025 (A$3.01 Mil) to Dec. 2025 (A$0.08 Mil).

Actinogen Medical's annual Short-Term Debt stayed the same from Jun. 2023 (A$0.00 Mil) to Jun. 2024 (A$0.00 Mil) but then increased from Jun. 2024 (A$0.00 Mil) to Jun. 2025 (A$3.01 Mil).

Actinogen Medical Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Actinogen Medical Short-Term Debt Related Terms

Actinogen Medical Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Actinogen Medical's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Actinogen Medical Short-Term Debt Chart

Actinogen Medical Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 3.01

Actinogen Medical Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.05 0.00 0.07 3.01 0.08
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of A$0.08 Mil mean?
Actinogen Medical (ASX:ACW) has a Short-Term Debt of A$0.08 Mil as of Dec. 2025.
Is Actinogen Medical's Short-Term Debt too high?
Actinogen Medical's current Short-Term Debt is A$0.08 Mil.
How does Actinogen Medical's Short-Term Debt compare to VRTX and REGN?
Actinogen Medical's Short-Term Debt of A$0.08 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Biotechnology company?
A good Short-Term Debt depends on the Biotechnology industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Actinogen Medical's current Short-Term Debt is A$0.08 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Actinogen Medical stock overvalued right now?
Actinogen Medical (ASX:ACW) has a current Short-Term Debt of A$0.08 Mil. The current Short-Term Debt is A$0.08 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Actinogen Medical (ASX:ACW), the current Short-Term Debt is A$0.08 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Actinogen Medical Business Description

Other Exchanges ATGGF:USA3AC:Germany
Address 109 Pitt Street, Level 9, Suite 901, Sydney, NSW, AUS, 2000
Actinogen Medical Ltd is a biotechnology company. The company develops a novel therapy for neurological and neuropsychiatric diseases associated with dysregulated cortisol in the brain. It is focused on the clinical development of Xanamem, an oral medication for neurological diseases amenable to its mechanism of lowering cortisol in brain cells. Geographically, the company's income is derived in Australia.